Cipla's stock is priced at Rs 1445.05, reflecting a minor decrease of 0.15% for today. The current 5-day simple moving average (SMA5) is Rs 1474.38. Cipla's stock is priced at Rs 1445.00, reflecting a ...

This is a method of using a mist-producing device that delivers the asthma medication more slowly over a longer period of time than an inhaler. However, because a nebulizer needs access to an ...

M/s. KamlaAmrut Pharmaceutical LLP, Survey No.: 53,56,57, Nr. KamlaAmrut Industrial Park, Indrad, Ta.: Kadi, Dist.: Mehsana, Gujarat - 382715, Susmita Roy, B pharm, M ...

Cipla ended the previous trading session at Rs 1529.1, reflecting a 0.5% increase, with 1,578,715 shares traded.

Health insurance rules capping monthly out-of-pocket costs for insulin, asthma inhalers, and epinephrine injectors took effect on New Year’s Day. The provisions, required under a law Gov. Phil Murphy ...

Afrezza (Afrezza) is a fast-acting inhaled insulin that is taken through an inhaler at mealtime ... preventing sudden spikes in sugar levels after meals. Cipla inhaled insulin: An alternative to ...

Drugmaker Cipla on Monday said that it has signed a perpetual license agreement with Switzerland-based Novartis Pharma AG to manufacture and market Galvus and Galvus combination brands which are used ...

Novartis and Cipla signed a perpetual licence agreement for the diabetes drug Galvus. Credit: Novartis AG. India-based pharmaceutical company Cipla has entered into a perpetual licence agreement with ...